CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously
Biotech thinks its PPAR delta agonist will prove much more potent than Genfit’s elafibranor from the same class and will offer a better tolerability profile than Intercept’s OCA.
You may also be interested in...
Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.
As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.
Firm points to liver biomarker findings, saying they may yield clear liver benefit at 52 weeks. Both CymaBay's and Genfit's stock prices fell as investors wondered about broader read-through for the PPAR agonist class.